Verrica Pharmaceuticals Inc

Price Chart

Risk-Adjusted Performance

Verrica Pharmaceuticals Inc (VRCA) Price Performance

Verrica Pharmaceuticals Inc (VRCA) trades on United States in USD. The company is classified in the Healthcare sector under the Pharmaceutical Preparations industry. The stock currently trades at $4.48, down 17.80% from the previous close.

Over the past year, VRCA has traded between a low of $3.28 and a high of $9.10. The stock has gained 0.8% over this period. It is currently 50.8% below its 52-week high.

Verrica Pharmaceuticals Inc has a market capitalization of $83.32M.

About Verrica Pharmaceuticals Inc

Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States. The company offers YCANTH (VP-102) a drug-device combination that contains a GMP-controlled formulation of cantharidin for the treatment of molluscum in adult and pediatric patients, as well as for the treatment of common warts. It also develops VP-315, an oncolytic peptide-based injectable therapy that is in phase II clinical trial for the treatment of dermatology oncologic conditions, which include basal cell carcinoma and other dermatological oncology indications. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum and common warts in Japan; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for use in malignant and pre-malignant dermatological indications. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.